COMMUNIQUÉS West-GlobeNewswire

ProFeel Life Establishes Itself as Switzerland's Specialist in Additive-Free Dietary Supplements
26/03/2026
With one in three Swiss consumers regularly taking dietary supplements, the Valais-based store ProFeel Life is breaking with the standards of a market saturated with excipients and controversial additives Collombey- [...]
Resolutions from Zealand Pharma's Annual General Meeting 2026
26/03/2026
Company announcement – No. 5 / 2026 Resolutions from Zealand Pharma's Annual General Meeting 2026 Copenhagen, Denmark, March 26, 2026 - Zealand Pharma A/S ("Zealand Pharma" or the “Company”) (Nasdaq: ZEAL) (CVR-no. [...]
Milestone Scientific Schedules Fourth Quarter and FY 2025 Financial Results and Business Update Conference Call
26/03/2026
ROSELAND, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today [...]
Survey Reveals 58% of Dentists Have Lost a Patient Due to Poor-Fitting Prosthetics
26/03/2026
New research report from Dandy examines the impact of remakes on restorative dentistry; finds 22% of fast-growing dental practices send half to three-quarters of prosthetics back to the lab NEW YORK, March 26, 2026 ( [...]
Nucleus Brings Genetic Optimization to India and the Middle East Through Leading IVF Networks
26/03/2026
Indira IVF and Abu Ghosh Fertility Group join the Nucleus IVF+ Network, as families seek a more complete picture of their future child’s health. NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Nucleus Genomics today [...]
Zelluna to host Capital Markets Update 2026
26/03/2026
Oslo, Norway – 26 March 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, invites investors, [...]
Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment
26/03/2026
TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today provided [...]
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
26/03/2026
-- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company [...]
Polyrizon Provides 2025 and Recent Highlights
26/03/2026
Company Concluded 2025 with Robust Cash Position, Debt-Free Balance Sheet and Significant Pipeline Achievements Raanana, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “ [...]
SK pharmteco to Host Innovations in Pharmaceutical Manufacturing Symposium in Cambridge, Massachusetts
26/03/2026
Innovations in Pharmaceutical Manufacturing: Continuous Manufacturing, Advanced Processing & Scalable Technologies on April 8th to feature top experts RANCHO CORDOVA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- SK [...]
FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair
26/03/2026
March 26, 2026 Philips DeviceGuide uses AI to track and visualize mitral valve repair devices [1] in real time during minimally invasive procedures , supporting treatment [2] DeviceGuide integrates with Philips Azurion [...]
Trading by management and close relations of management
26/03/2026
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the [...]
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
26/03/2026
RAMAT GAN, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological [...]
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors
26/03/2026
HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for [...]
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
26/03/2026
200µg Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin Cancer PHILADELPHIA, March 26, 2026 (GLOBE NEWSWIRE) -- Medicus [...]
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
26/03/2026
– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP – – Company plans to initiate [...]
Notification of managers’ transactions
26/03/2026
ANNOUNCEMENT NO. 304 26 March 2026 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notifications pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in [...]
Preliminary results for the year ended 31 December 2025
26/03/2026
A year of strategic execution, strong revenue growth and positive Operating EBITDA Strong 2025 financial performance; revenues at upper end of guidance, with full year Operating EBITDA profitability achieved: Revenue [...]
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
26/03/2026
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Lead clinical candidate IND filing in Acumen’s Enhanced [...]

Pages